Competing interest reported. YN (Otsuka Pharmaceutical Co., Ltd.), HK (Celgene Corporation), SM (Fujitsu Limited), SO (Chordia Therapeutics Inc., Kan Research Institute, Inc., Otsuka Pharmaceutical Co., Ltd.), and KA (Sumitomo Dainippon Pharma Co., Ltd., Kyowa Kirin Co., Ltd.) are consultants for each company. SO has an ownership interests (including stock options) in a start-up company, the stock of which is not publicly traded for RegCell Co., Ltd., Asahi Genomics Co., Ltd., and Chordia Therapeutics, Inc. YM (Eisai Co., Ltd.), HS (Astellas Pharma Inc., Teijin Ltd., Shionogi Co., Ltd, Taiho, Pharmaceutical Co., Ltd., Eisai Co., Ltd., Celgene Corporation, Ono Pharmaceutical Co., Ltd., Takeda Pharmaceutical Co., Ltd., MSD K.K., Sumitomo Dainippon Pharma Co., Ltd., Nippon Shinyaku Co., Ltd, Daiichi Sankyo Co., Ltd.), YM (Kyowa Kirin Co., Ltd.), SM (DeNA Life Science Inc.), IM (Chugai Pharmaceutical Co., Ltd., Eisai Co., Ltd., Ono Pharmaceutical Co., Ltd., Kyowa Kirin Co., Ltd., Shionogi Co., Ltd., Sumitomo Dainippon Pharma Co., Ltd., Asahi Kasei Pharma Corporation, Takeda Pharmaceutical Co., Ltd., Nippon Shinyaku Co., Ltd., Pfizer Japan Inc., Taiho Pharmaceutical Co., Ltd., Mitsubishi Tanabe Pharma Corporation, Nihon Pharmaceutical Co., Ltd., Novartis Pharma K.K., Daiichi Sankyo Co., Ltd., MSD K.K., Japan Blood Products Organization, Otsuka Pharmaceutical Co., Ltd., Mundipharma K.K., AbbVie GK, Sanofi K.K., Ayumi Pharmaceutical Corporation, Eli Lilly Japan K.K.), SO (Sumitomo Dainippon Pharma Co., Ltd., Chordia Therapeutics Inc., Otsuka Pharmaceutical Co., Ltd., Eisai Co., Ltd.) , KA (Celgene Corporation, Kyowa Kirin Co., Ltd, Astellas Pharma Inc., Shionogi Co., Ltd., Asahi Kasei Pharma Corporation , Chugai Pharmaceutical Co., Ltd, Bristol-Myers Squibb Co.), KM (Novartis Pharma K.K., Kyowa Kirin Co., Ltd., Chugai Pharmaceutical Co., Ltd., Takeda Pharmaceutical Co., Ltd.) have received the research funding of each companies. YM (Kyowa Kirin Co., Ltd.), MI (Novartis Pharma K.K., Takeda Pharmaceutical Co., Ltd.), HS (Takeda Pharmaceutical Co., Ltd., Novartis Pharma K.K., Celgene Corporation, Janssen Pharmaceutical K.K., Chugai Pharmaceutical Co., Ltd., Kyowa Kirin Co., Ltd., Ono Pharmaceutical Co., Ltd, Eisai Co., Ltd., Nippon Shinyaku Co., Ltd., Otsuka Pharmaceutical Co., Ltd., Daiichi Sankyo Co., Ltd., Bristol-Myers Squibb Co., Pfizer Japan Inc., Fujimoto Pharmaceutical Corporation), YM (Kyowa Kirin Co., Ltd), TM (Bristol-Myers Squibb Co., Otsuka Pharmaceutical Co., Ltd., MSD K.K., Astellas Pharma Inc., Amgen Astellas Biopharma K.K., Celgene Corporation, AbbVie GK, Takeda Pharmaceutical Co., Ltd.), HK (Kyowa Kirin Co., Ltd., Sanofi K.K., Novartis Pharma K.K., Chugai Pharmaceutical Co., Ltd.), SM (Ministry of Health, Labour and Welfare, Japan Science and Technology Agency, National Institutes of Biomedical Innovation, Health and Nutrition), IM (Pfizer Japan Inc., Novartis Pharma K.K., Daiichi Sankyo Co., Ltd., Astellas Pharma Inc., Otsuka Pharmaceutical Co., Ltd., Bristol-Myers Squibb Co.) have directly received honoraria from an entity. Seishi Ogawa (Qiagen K.K.) has received patents and royalties. KM (Celgene Corporation, Kyowa Kirin Co., Ltd.) has received fee of expert testimony. HS (Chugai Pharmaceutical Co., Ltd., Ono Pharmaceutical Co., Ltd., AbbVie GK, AstraZeneca), and SM (Uehara Foundation, Nakagani Foundation, Otsuka Foundation, Okawa Foundation) are assigned as an entity's board of directors, speakers bureau, or its advisory committees. HH, TH, KT, HT, JK and YK have no COI to disclose.